Eosinophil apoptosis as a therapeutic target in allergic asthma

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 1, 2014, Pages 109-117

  Ilmarinen, Pinja ^a   Kankaanranta, Hannu ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIN DEPENDENT KINASE; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 5 RECEPTOR ALPHA; LEUKOTRIENE; MESOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; THEOPHYLLINE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; APOPTOSIS; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHIL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-ASTHMATIC AGENTS; APOPTOSIS; ASTHMA; DISEASE MODELS, ANIMAL; EOSINOPHILS; GLUCOCORTICOIDS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-3; INTERLEUKIN-5; LUNG;

EID: 84890794285     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12163     Document Type: Review

References (85)

1. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
2. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50.
3. Akuthota P, Wang HB, Spencer LA, Weller PF. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clin Exp Allergy 2008;38:1254-63.
4. Wenzel SE. Eosinophils in asthma-closing the loop or opening the door? N Engl J Med 2009;360:1026-8.
5. Erjefalt JS, Uller L, Malm-Erjefalt M, Persson CG. Rapid and efficient clearance of airway tissue granulocytes through transepithelial migration. Thorax 2004;59:136-43.
6. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ 2012;19:107-20.
7. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 1996;154:237-43.
8. Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem 2011;286:32899-905.
9. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-8.
10. Zhang X, Moilanen E, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol 2000;406:325-32.
11. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res 2010;2:87-101.
12. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65:384-90.
13. Walsh GM, Sexton DW, Blaylock MG, Convery CM. Resting and cytokine-stimulated human small airway epithelial cells recognize and engulf apoptotic eosinophils. Blood 1999;94:2827-35.
14. Duffin R, Leitch AE, Fox S, Haslett C, Rossi AG. Targeting granulocyte apoptosis: mechanisms, models, and therapies. Immunol Rev 2010;236:28-40.
15. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000;106:77-83.
16. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-8.
17. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 1991;85:312-6.
18. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991;78:2542-7.
19. Stern M, Meagher L, Savill J, Haslett C. Apoptosis in human eosinophils. programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992;148:3543-9.
20. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
21. Wong CK, Hu S, Cheung PF, Lam CW. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol 2010;43:305-15.
22. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90.
23. Conus S, Bruno A, Simon HU. Leptin is an eosinophil survival factor. J Allergy Clin Immunol 2005;116:1228-34.
24. Kottyan LC, Collier AR, Cao KH, Niese KA, Hedgebeth M, Radu CG et al. Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner. Blood 2009;114:2774-82.
25. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C et al. Disordered microbial communities in asthmatic airways. PLoS One 2010;5:e8578.
26. Ilmarinen P, Hasala H, Sareila O, Moilanen E, Kankaanranta H. Bacterial DNA delays human eosinophil apoptosis. Pulm Pharmacol Ther 2009;22:167-76.
27. Mansson A, Cardell LO. Role of atopic status in toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophils. J Leukoc Biol 2009;85:719-27.
28. Kankaanranta H, Moilanen E, Zhang X. Pharmacological regulation of human eosinophil apoptosis. Curr Drug Targets Inflamm Allergy 2005;4:433-45.
29. Walsh G. Eosinophil apoptosis and clearance in asthma. J Cell Death 2013;6:17-25.
30. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5.
31. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 2002;71:1523-34.
32. Wiegers GJ, Knoflach M, Bock G, Niederegger H, Dietrich H, Falus A et al. CD4(+)CD8(+)TCR(low) thymocytes express low levels of glucocorticoid receptors while being sensitive to glucocorticoid-induced apoptosis. Eur J Immunol 2001;31:2293-301.
33. Zhang X, Moilanen E, Kankaanranta H. Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 2001;431:365-71.
34. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9.
35. Gardai SJ, Hoontrakoon R, Goddard CD, Day BJ, Chang LY, Henson PM et al. Oxidant-mediated mitochondrial injury in eosinophil apoptosis: enhancement by glucocorticoids and inhibition by granulocyte-macrophage colony-stimulating factor. J Immunol 2003;170:556-66.
36. Sivertson KL, Seeds MC, Long DL, Peachman KK, Bass DA. The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of mcl-1L in neutrophils but not in eosinophils. Cell Immunol 2007;246:34-45.
37. Ilmarinen-Salo P, Moilanen E, Kinnula VL, Kankaanranta H. Nitric oxide-induced eosinophil apoptosis is dependent on mitochondrial permeability transition (mPT), JNK and oxidative stress: apoptosis is preceded but not mediated by early mPT-dependent JNK activation. Respir Res 2012;13:73.
38. Janka-Junttila M, Moilanen E, Hasala H, Zhang X, Adcock I, Kankaanranta H. The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils. J Inflamm (Lond) 2006;3:10.
39. Druilhe A, Wallaert B, Tsicopoulos A, Lapa e Silva JR, Tillie-Leblond I, Tonnel AB et al. Apoptosis, proliferation, and expression of bcl-2, fas, and fas ligand in bronchial biopsies from asthmatics. Am J Respir Cell Mol Biol 1998;19:747-57.
40. Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 1999;103:563-73.
41. Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 2003;22:484-90.
42. Liu Y, Cousin JM, Hughes J, Van Damme J, Seckl JR, Haslett C et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 1999;162:3639-46.
43. Wang J, Wang C, Li X, Kong L, Gao K, Liu RY. The effects of anti-asthma drugs on the phagocytic clearance of apoptotic eosinophils by A549 cells. Respir Med 2009;103:1693-9.
44. Wang C, Wang J, Guo HF, Liu RY. Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett 2007;111:103-10.
45. McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. ScientificWorldJournal 2007;7:1165-81.
46. Kankaanranta H, Parkkonen J, Ilmarinen-Salo P, Giembycz MA, Moilanen E. Salbutamol delays human eosinophil apoptosis via a cAMP-dependent mechanism. Pulm Pharmacol Ther 2011;24:394-400.
47. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43.
48. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy 2010;40:1732-41.
49. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000;161:1881-6.
50. Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013;188:901-6.
51. Adachi T, Motojima S, Hirata A, Fukuda T, Kihara N, Kosaku A et al. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol 1996;98:S207-15.
52. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 1997;100:1677-84.
53. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164:273-6.
54. Kano G, Almanan M, Bochner BS, Zimmermann N. Mechanism of siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol 2013;132:437-45.
55. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012;135:327-36.
56. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344, 1353.e2
57. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237, 1244.e2
58. Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3:235-43.
59. Kankaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M et al. Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. J Inflamm (Lond) 2010;7:9.
60. Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 2005;18:160-6.
61. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005;35:89-96.
62. Banerjee A, Trivedi CM, Damera G, Jiang M, Jester W, Hoshi T et al. Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am J Respir Cell Mol Biol 2012;46:132-8.
63. Alessandri AL, Duffin R, Leitch AE, Lucas CD, Sheldrake TA, Dorward DA et al. Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation. PLoS One 2011;6:e25683.
64. Farahi N, Uller L, Juss JK, Langton AJ, Cowburn AS, Gibson A et al. Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance. Clin Exp Allergy 2011;41:673-87.
65. Korhonen R, Moilanen E. MAP kinase phosphatase-1 as an inflammatory factor and drug target. Basic Clin Pharmacol Toxicol; in press.
66. Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-9.
67. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, Lindsay MA. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 1999;290:621-8.
68. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121:1-13.
69. Fujihara S, Jaffray E, Farrow SN, Rossi AG, Haslett C, Hay RT. Inhibition of NF-kappa B by a cell permeable form of I kappa B alpha induces apoptosis in eosinophils. Biochem Biophys Res Commun 2005;326:632-7.
70. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010;4:19-34.
71. Rosas M, Dijkers PF, Lindemans CL, Lammers JW, Koenderman L, Coffer PJ. IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with beta-catenin relocalization. J Leukoc Biol 2006;80:186-95.
72. Pinho V, Souza DG, Barsante MM, Hamer FP, De Freitas MS, Rossi AG et al. Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation. J Leukoc Biol 2005;77:800-10.
73. Lehtimaki L, Kankaanranta H, Saarelainen S, Hahtola P, Jarvenpaa R, Koivula T et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med 2001;163:1557-61.
74. Oliveira MS, de O Barreto E, Zamuner S, Pires AL, Ferreira TP, Cordeiro RS et al. Suppressive effects of nitric oxide-releasing prednisolone NCX-1015 on the allergic pleural eosinophil recruitment in rats. Clin Exp Allergy 2008;38:1830-7.
75. Pontin J, Blaylock MG, Walsh GM, Turner SW. Sputum eosinophil apoptotic rate is positively correlated to exhaled nitric oxide in children. Pediatr Pulmonol 2008;43:1130-4.
76. Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007;176:988-93.
77. Redington AE. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol 2006;533:263-76.
78. Ilmarinen-Salo P, Moilanen E, Kankaanranta H. Nitric oxide induces apoptosis in GM-CSF-treated eosinophils via caspase-6-dependent lamin and DNA fragmentation. Pulm Pharmacol Ther 2010;23:365-71.
79. Zhang X, Moilanen E, Lahti A, Hamalainen M, Giembycz MA, Barnes PJ et al. Regulation of eosinophil apoptosis by nitric oxide: role of c-jun-N-terminal kinase and signal transducer and activator of transcription 5. J Allergy Clin Immunol 2003;112:93-101.
80. Beauvais F, Joly F. Effects of nitric oxide on the eosinophil survival in vitro. A role for nitrosyl-heme. FEBS Lett 1999;443:37-40.
81. Kankaanranta H, Ilmarinen P, Zhang X, Nissinen E, Moilanen E. Antieosinophilic activity of orazipone. Mol Pharmacol 2006;69:1861-70.
82. Kankaanranta H, Zhang X, Tumelius R, Ruotsalainen M, Haikala H, Nissinen E et al. Antieosinophilic activity of simendans. J Pharmacol Exp Ther 2007;323:31-8.
83. Sareila O, Korhonen R, Auvinen H, Hamalainen M, Kankaanranta H, Nissinen E et al. Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. Br J Pharmacol 2008;155:884-95.
84. Sareila O, Hamalainen M, Nissinen E, Kankaanranta H, Moilanen E. Orazipone inhibits activation of inflammatory transcription factors nuclear factor-kappa B and signal transducer and activator of transcription 1 and decreases inducible nitric-oxide synthase expression and nitric oxide production in response to inflammatory stimuli. J Pharmacol Exp Ther 2008;324:858-66.
85. Knolle MD, Nakajima T, Hergrueter A, Gupta K, Polverino F, Craig VJ et al. Adam8 limits the development of allergic airway inflammation in mice. J Immunol 2013;190:6434-49.